Head Medical Oncology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Head medical oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Head Medical Oncology Today - Breaking & Trending Today

New Advances In Treating Stage IV Cancer

New Advances In Treating Stage IV Cancer
kashmirreader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kashmirreader.com Daily Mail and Mail on Sunday newspapers.

Raghav Kesri , Multifaceted Approach , Senior Consultant , Head Medical Oncology , Yatharth Hospital ,

Strengthening men's health through 'Movember' | Borneo Bulletin Online

Pantai Jerudong Specialist Centre (PJSC) on Wednesday launched ‘Movember’ to mark Men’s Health awareness for the whole month of November. This year, The Brunei Cancer Centre (TBCC) organised a public forum focusing on strengthening men’s health through a holistic approach. The forum serves as a platform to foster awareness, knowledge, and open dialogue on various […] ....

Brunei General , Fadley Faisal , Awang Besar , Abdul Ghafor , Ravi Sekhar Patnaik , Brunei Cancer Centre , Narcotics Control Bureau , Pantai Jerudong Specialist Centre , Men Health , Executive Director , Haji Mazrul Adimin , Haji Awang Besar , Medical Director , Meera Sahib , Haji Mohamad , Head Medical Oncology , Palliative Care Unit , Brunei Cancer , Medical Oncologist , Motivator Haji Ali Yusri , Senior Narcotic Officer , Abdul Halim , Haji Mohamed , Prostate Cancer , Asia News November Awareness Borneo Bulletin Campaign Cancer Health Mens Movember National Top Wellness ,

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients
The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumor has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumor converted to HER2-low expression in the recurrent tumor possibly offering an option to such hard-to-treat tumors. ....

Comunidad Autonoma De Cataluna , Aleix Prat , Emily Henderson , School Of Oncology , University Of Padua , Cancer Virtual Congress , Federica Miglietta , Professor Aleix Prat , Head Medical Oncology , Hospital Clinic , காமுனிடட தன்னாட்சி டி கடலுள் , எமிலி ஹென்டர்சன் , பள்ளி ஆஃப் புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் ப்யாட்யூவ , தலை மருத்துவ புற்றுநோயியல் , மருத்துவமனை சிகிச்சையகம் ,

Switch of breast tumors to HER2-low might provide greater therapeutic options

Switch of breast tumors to HER2-low might provide greater therapeutic options
ANI |
Updated: May 09, 2021 18:56 IST
Lugano [Switzerland], May 9 (ANI): The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. The study was published in the journal Annals of Oncology. ....

Italy General , Comunidad Autonoma De Cataluna , Aleix Prat , School Of Oncology , University Of Padua , Cancer Virtual Congress , Professor Aleix Prat , Head Medical Oncology , Hospital Clinic , இத்தாலி ஜநரல் , காமுனிடட தன்னாட்சி டி கடலுள் , பள்ளி ஆஃப் புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் ப்யாட்யூவ , தலை மருத்துவ புற்றுநோயியல் , மருத்துவமனை சிகிச்சையகம் ,

Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options

European Society for Medical Oncology
The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumour converted to HER2-low expression in the recurrent tumour possibly offering an option to such hard-to-treat tumours. ....

Comunidad Autonoma De Cataluna , Aleix Prat , School Of Oncology , University Of Padua , Cancer Virtual Congress , Professor Aleix Prat , Head Medical Oncology , Hospital Clinic , காமுனிடட தன்னாட்சி டி கடலுள் , பள்ளி ஆஃப் புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் ப்யாட்யூவ , தலை மருத்துவ புற்றுநோயியல் , மருத்துவமனை சிகிச்சையகம் ,